ArticleEFSA journal. European Food Safety Authority2025
Evaluation of confirmatory data following the Article 12 MRL review for spinetoram.
Article in EFSA journal. European Food Safety Authority, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The applicant Corteva Agriscience International Sàrl submitted a request to the competent national authority in Croatia to evaluate the confirmatory data that were identified in the framework of the MRL review under Article 12 of Regulation (EC) No 396/2005. The applicant submitted, a confirmatory analytical method for high oil content and dry plant commodities, fat, liver, kidney and an enforcement analytical method for eggs (quantification and confirmation) and its ILV in the current application. Furthermore, residue trials for table and wine grapes, apples, pears and apricots were also provided. The data gaps on the analytical methods were considered as satisfactorily addressed for all relevant matrices except for the extraction efficiency which was not satisfactorily addressed. Since the approval period of spinetoram in the EU expired on 30 June 2024, the data gap on residue trials to support EU uses was not considered relevant anymore and a revision of the previous consumer risk assessment was not required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.